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a  b  s  t  r  a  c  t
A  method  for  the  quantitative  determination  of the protein  composition  of adenovirus-vector  based
vaccines  was  developed.  The  final  method  used  RP-UPLC  with  UV absorbance  detection,  a C4  column
(300  Å, 1.7  m,  2.1 × 150  mm),  and  a water-  acetonitrile  (ACN)  gradient  containing  trifluoroacetic  acid
(TFA)  as  ion-pairing  agent.  The  chromatographic  resolution  between  the  various  adenovirus  proteins  was
optimized  by  studying  the  effect  of  the  TFA  concentration  and  the  column  temperature,  applying  a full
factorial  design  of experiments.  A  reproducible  baseline  separation  of all relevant  adenovirus  proteins
could  be  achieved  within  17  min  run  time.  Samples  containing  adenovirus  particles  could  be directly
injected  into  the  UPLC system  without  sample  pretreatment.  The  viruses  reproducibly  dissociate  into
proteins  in  the  UPLC  system  upon  contact  with  the  mobile  phase  containing  ACN.  The  new  RP-UPLC
method  was  successfully  validated  for  protein  profiling  and  relative  quantification  of  proteins  in vaccineuantification products  based  on adenovirus  vector  types  26  and  35.  The  intermediate  precision  of  the  relative  peak
areas  of all  proteins  was  between  1% and  14% RSD,  except  for  the  peak  assigned  to protein  V (26%  RSD).  The
method  proved  to be stability  indicating  with  respect  to  thermal  and  oxidation  stress  of  the  adenovirus-
vector  based  vaccine  and  was  successfully  implemented  for  the  characterization  of  adenovirus-based
products.
©  2018  Elsevier  B.V.  All  rights  reserved.. Introduction
Adenoviruses are non-enveloped icosahedral-shaped viruses
f 70–90 nm,  consisting of a protein capsid containing a double
tranded DNA genome [1,2]. Adenoviruses are promising vectors
or intracellular delivery of DNA [3]. The Advac
®
technology in
ombination with the PER.C6
®
technology [4,5] allows for the
roduction of adenovirus vectors in which the viral DNA can be
odified to encode for an antigen of interest. For example, in
he case of the Ebola vaccine the adenovirus vector is modified
o encode for a certain glycoprotein from the Ebola virus [6].
pon vaccination, this glycoprotein is expressed in the host cell
nd presented to the immune system, thereby expectedly elic-
ting a protective immune response against the Ebola virus. The
∗ Corresponding author.
E-mail address: evantri@its.jnj.com (E. van Tricht).
ttps://doi.org/10.1016/j.chroma.2018.10.045
021-9673/© 2018 Elsevier B.V. All rights reserved.adenovirus proteome is composed of different proteins in vary-
ing stoichiometries [1,7]. The adenovirus proteins are identified by
numbers, in order of decreasing molecular weight as observed by
SDSPAGE [8]. The virus capsid consists of 240 trimers of protein II
(hexon) and 60 copies of protein III (penton base). The fiber protein
(IV) is extending outwards from the penton bases and is consid-
ered essential in the binding of the adenovirus to the cell surface.
Four minor proteins (IIIa, VI, VIII and IX) are located on the inner
side of the capsid and are thought to act as cement proteins. The
core of the particle contains six different proteins: V, VII, X, IVa2,
the terminal protein (TP), and the adenovirus protease (AVP) [1].
The viral protein identity, heterogeneity and content in the aden-
ovirus particles determine the identity of the particle, its interaction
with the cell and, possibly, its stability. If the incorrect proteins
are expressed or the virus particles are not correctly assembled,
then this could lead to adenoviruses with decreased or no biolog-
ical activity, and, therefore, a vaccine with decreased potency. In
addition, degraded or modified proteins in the adenovirus vector
26 E. van Tricht et al. / J. Chromatogr. A 1581–1582 (2018) 25–32
















































.1  × 250 mm.  Solvent A, 5% ACN in milli-Q with 0.1% TFA; solvent B, 0.1% TFA in 99
5  min, 46%–60% solvent B at 110 min. Injection volume, 100 l; flow rate, 0.2 ml/m
t  280 nm.
articles could also result in decreased biological activity or adverse
ffects upon vaccine administration. It is a challenge to develop a
uitable analytical method for the analysis of the adenovirus pro-
eins due to the great dynamic range needed to measure all protein
ubunit concentrations simultaneously, and due to the large vari-
bility of protein sizes and charges [9]. The molecular masses of the
denovirus proteins range between 7 and 108 kDa, and the copy
umbers per virus particle are between 2 (for the TP) and 720 (for
he protein II monomer) [1,10,11]. An additional layer of complex-
ty is added by the need to disassemble the adenovirus into stable
nd analyzable protein before analysis. Typically, an extensive sam-
le treatment is required to denature the viruses into proteins, to
emove matrix components (e.g. surfactants) from the samples, or
o concentrate the samples [12,13]. Intact proteins in biopharma-
eutical products are commonly analyzed by spectrometry [14],
lectrophoresis [15], liquid chromatography [16,17], or mass spec-
rometry [14,18–20]. More specifically, viral proteins are typically
nalyzed by SDS-PAGE [10,21,22], capillary gel electrophoresis
CGE) [23–25] or RP-HPLC [12,13,26]. SDS-PAGE has been exten-
ively used for adenovirus protein analysis [27,28]. The key proteins
f the adenovirus are separated from each other by SDS-PAGE,
nd MS  can be used after in-gel trypsin digestion for band assign-
ent. Such methods do not allow for accurate quantification of
he adenovirus proteins due to the poor separation on the gel. In
ddition, protein modifications (for example, detected by MS) could
e introduced by the harsh SDS-PAGE and MS  pretreatment con-
itions. Capillary gel electrophoresis was applied for the analysis
f recombinant GB virus-C proteins [29], the analysis of the four
ajor influenza virus proteins [25], and the characterization of pro-
eins from Western, Eastern, and Venezuelan equine encephalitis
WEVEE) virus like particles (VLPs) [23]. The downside of the cap-
llary gel electrophoresis methods is the limited molecular weight
ange. The method has a low efficiency for proteins with sizes lower
han 15 kDa or larger than 100 kDa resulting in insufficient resolu-
ion. Another drawback is the extensive sample treatment that is
equired to denature, reduce and alkylate the virus samples before
nalysis by CGE. Liquid chromatography-based methods for anal-
sis of intact proteins in virus and virus-based vaccines have been
eported in the literature. Although RP-LC is already an established
echnique for protein analysis, recent technology developments
specially improved the stationary phases (i.e. particle sizes down
o 1.7 m with pore sizes of 300 Å) allowing for even better, more
eproducible separation of intact proteins [14]. Another technical
mprovement is the introduction of low-binding materials in the LC. Linear gradient with 3 slopes, 20%–34% solvent B at 37 min, 34%–46% solvent B at
lumn temperature, 40 ◦C; sample tray temperature, 8 ◦C; UV absorbance detection
equipment that decreased artifacts such as adsorption to injectors,
tubing etc. [14]. RP-HPLC was used for analysis of the nucleocap-
sid protein (N-protein) from the severe acute respiratory syndrome
(SARS) coronavirus [13]. Separation was  on a reversed phase C18
column (5 m particle size and 300 Å pore size) with ACN/water
and trifluoroacetic acid (TFA) as mobile phase. Prior to analysis, the
samples were dialyzed, lyophilized, and concentrated. The method
did not achieve baseline resolution between the analyte of inter-
est and interfering peaks from the sample matrix. The N-protein
could only be identified after fraction collection and MALDI-TOF
analysis. RP-HPLC [12,30,31] was also used for quantification of the
influenza hemagglutinin protein (HA) from the influenza virus. HA
is cleaved by trypsin into a hydrophilic HA1 and a hydrophobic
HA2 fragment. With RP-HPLC, fragment HA1 is well-resolved from
other sample components and a quantitative method with exter-
nal calibration has been reported in the literature [31]. The sample
preparation in this method is laborious and time-consuming and
the other major proteins from the influenza virus, HA2, M and NP,
could not be detected. An RP-HPLC with UV absorbance detection,
based on Lehmberg et al. [26] and Liu et al. [10], is being used for
quality control of the protein profile of adenovirus vaccine prod-
ucts, see Fig. 1 for an example chromatogram. Disadvantages of
the RP-HPLC method are its inadequate resolution for certain pro-
teins (e.g. protein II and IX) and the insufficient repeatability of the
retention times and peak areas. Therefore, reliable quantification
of all proteins by RP-HPLC is not possible. Another drawback of the
RP-HPLC method is its very long run time of 130 min, which lim-
its the throughput to 10 samples per sequence (including controls
and blanks) as sample instability is observed after sample storage
for 18 h in the auto sampler. This paper describes the develop-
ment and validation of an RP-UPLC method for protein profiling
of adenovirus serotype 26 (Ad26) and 35 (Ad35) in adenovirus
vector-based vaccine products. The method has two purposes: con-
firm identity of the test sample and detect protein modifications or
degradation products of the adenovirus vector. For identity pur-
poses, the protein profile of the test sample is compared to the
profile of a reference sample based on the relative retention times
and relative peak areas. By calculating the relative peak areas of all
peaks in the chromatogram and identifying new peaks in the chro-
matogram, the method also allows the detections of degradation
products in the sample Additional requirements for the method
development were: a chromatographic run time of less than 30 min,
baseline separation of all relevant adenovirus proteins allowing for
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. Materials and methods
.1. Chemicals
Acetonitrile UPLC/MS grade (PN 01204101) from Biosolve
Valkenswaard, the Netherlands), Acetonitrile gradient grade
SN 34851-2.5L), Trifluoroacetic acid 99+% (PN 302031) and
ytochrome-C (PN C2506) from Sigma-Aldrich (Zwijndrecht, the
etherlands), methanol (PN 106008) and Milli-Q water from Merck
illipore (Amsterdam-Zuidoost, The Netherlands). Formulation
uffer, Ad35 reference material (with transgenes B and C), Ad26
eference material (with transgenes A and B) and Ad26 process
amples were from Janssen Vaccines (Leiden, the Netherlands).
mmonium bicarbonate (PN 40847) from Honeywell (Bucharest,
omania), Trypsin (PN V5111) from Promega (Madison, WI,  USA),
ormic acid (PN 06914143) and water UPLC/MS grade (PN 23214B1)
rom Biosolve (Valkenswaard, the Netherlands), Q-Tof Qualifica-
ion Standards Kit (PN 700003276) and leucine encephalin (PN
86006013) from Waters Corp. (Milford, MA,  USA).
.2. Liquid chromatography
A Waters Acquity H-class UPLC system equipped with a qua-
ernary solvent manager, autosampler, and PDA detector (Waters
orp., MA,  USA) was used. Data processing was performed by
mpower 3 software. Various settings were tested in method
evelopment; the settings for the final, validated method were as
ollows. The analytical column was an Acquity UPLC Protein BEH
4 Column (300 Å, 1.7 m,  2.1 × 150 mm).  New analytical columns
ere preconditioned with 3 injections (30 l each) of 10 mg/ml
ytochrome-C followed by 3 injections (30 l) of Milli-Q water to
revent unwanted protein adsorption with the stationary phase.
olvent A was 5% v/v acetonitrile (ACN) in Milli-Q water, solvent
 was 100% ACN, and solvent C was 1% w/v TFA in 5% ACN. From
, B and C a linear elution gradient was formed from 20% ACN to
0% ACN containing 0.175% w/v TFA in 17 min. The flow rate was
.6 ml/min, the injection volume was 30 l, the column temper-
ture was 50 ◦C, the auto sampler temperature was 8 ◦C, and for
etection UV-absorbance was monitored at 280 nm.  After analy-
es, the system was flushed with 30% v/v ACN in Milli-Q, the needle
ash was with 20% v/v ACN in Milli-Q, and pump seal wash was
ith 10% v/v methanol in Milli-Q.
.3. MS-based protein peak assignment
For preparative runs intended for peak assignment, samples
f selected AdVac vaccines were first concentrated in 1.5 ml
ppendorf® LoBind microcentrifuge tubes Protein (Hamburg,
ermany) by centrifugation in an Eppendorf 5417R microcen-
rifuge at 17000 g for 30 min  at 4 ◦C and removal of the supernatant.
oncentrated samples were analyzed by the RP-UPLC method on
 Waters Acquity H-class UPLC system (method as described in
ection 2.2). Fractions were collected every 10 s for 16 min  in
ppendorf twin.tec PCR Plates LoBind using the fraction collector
f a TriVersa NanoMate® (Advion, Ithaca, NY, USA). The fractions
ere dried in a vacuum centrifuge without heating for 4 h. The pel-
ets were resuspended in 6 l of 30% ACN, then 12 l of trypsin
olution (20 g/ml in 50 mM Ammonium bicarbonate) was added,
nd samples were incubated overnight at 37 ◦C. The tryptic digests
ere again dried in a vacuum centrifuge and resuspended in 18 l
f 20% ACN with 0.1% formic acid. The trypsin digests were ana-
yzed by LC–MSE on a Waters Acquity H-class UPLC system coupled
o a Waters Synapt G2-SI mass spectrometer (Waters Corp., MA,
SA). The analytical column was an Acquity UPLC Protein BEH C18
olumn (300 Å, 1.7 m,  2.1 × 150 mm).  Solvent A was 0.1% formic
cid in Milli-Q water and solvent B was 0.1% formic acid in 100%A 1581–1582 (2018) 25–32 27
ACN. Elution was  by a linear gradient from 2% B to 35% B in 45 min.
The flow rate was 0.2 ml/min, the injection volume was 10 l, the
column temperature was  40 ◦C, the autosampler temperature was
6 ◦C. For MSE conditions were: collision energy, 20 40 V (ramped);
lock-mass solution, leucine enkephalin (2 ng/ml) in 1:1 ACN-Milli-
Q water with 0.1% formic acid; lock-mass flow, 5 l/min; capillary
voltage, 3.0 kV, sample cone temperature, 25 ◦C; source tempera-
ture, 120 ◦C; desolvation gas, 800 L/h; cone gas flow rate, 20 L/h;
employing resolution mode with 1 scan per s.
2.4. Preparation of stressed samples
Samples of adenovirus vector type 26 based vaccine were first
diluted to 2.0 × 1011 virus particles (vp)/ml in formulation buffer
and then the following stress conditions were applied: thermal
stress by incubation at 50 ◦C for 45 or 120 min; oxidative stress by
addition of 30% v/v hydrogen peroxide and incubating for 4 h. The
stressed samples were analyzed by capillary zone electrophoresis
(CZE) according to Van Tricht et al. [32], by potency assay according
to Ma  et al. [33], and by RP-UPLC as described above (Section 2.2.).
To compare the different techniques recoveries between stressed
samples and non-stressed samples were used (i.e. total peak area
recovery for RP-UPLC, potency recovery for the potency assay or
virus particle concentration recovery for CZE).
2.5. Method validation
Specificity was  demonstrated during development for Ad26 and
Ad35 proteins by MS-based peak assignments and by demonstrat-
ing absence of the viral proteins in the formulation buffer. The
method repeatability, accuracy, intermediate precision, and lin-
earity were determined for 5 concentration levels in the range of
0.5 × 1011 – 2.0 × 1011 vp/ml with 3 replicates at each concentra-
tion level, repeated on 3 different days by two  operators on two
analytical columns, and two  LC instruments. The method repeata-
bility requirements were ≤ 15% RSD for relative peak areas and ≤
1% RSD for relative retention times. The intermediate precision was
determined based on the method repeatability and linearity data
on three different days and the limits were ≤20% RSD for relative
peak areas and ≤ 2.0% RSD for relative retention times. The linearity
requirements were r2 ≥ 0.98 and the sum of residuals less than 5%.
The accuracy requirement was  recoveries of 80–120% for relative
peak areas. The limit of quantification (LOQ) was determined as the
lowest concentration level that met  the requirements for accuracy
and precision. Robustness was  derived from the results of method
development obtained with design of experiments.
3. Results and discussion
3.1. Translation from HPLC to UPLC and determination of critical
method parameters
In the original RP-HPLC method, based on Lehmberg et al. [26]
and Liu et al. [10], the adenovirus proteins were separated on a
C4 column (5 m,  2.1 × 250 mm)  with a water-ACN gradient, with
three segments of different slopes, from 20% to 60% ACN containing
0.1% TFA in 110 min, see Fig. 1. The adenovirus samples are directly
injected into the UPLC system without sample pre-treatment (e.g.
denaturation, reduction or dilution) and the viruses dissociate into
proteins upon coming in contact with the water-ACN mobile phase
in the UPLC system. Dissociating the viruses into proteins prior to
the UPLC analysis resulted in irreproducible chromatograms (data
not shown) [26]. This method was  transferred to an UPLC Xbridge
BEH 300 C4 column (1.7 m,  2.1 × 150 mm).  The linear gradient
with three slopes was replaced by a single-slope linear gradient
to improve elution reproducibility and the flow rate was increased
28 E. van Tricht et al. / J. Chromatogr. A 1581–1582 (2018) 25–32
Fig. 2. RP-UPLC-UV of Ad26 sample measured with different TFA concentrations using a column temperature of 50 ◦C (A–F) and Ad26 sample measured with different column











































5 ◦C (G), 50 ◦C (H and A – F), 60 ◦C (I), or 70 ◦C (J). The Ad26 sample was  diluted in
00  Å, 1.7 m,  2.1 mm x 150 mm.  Solvent A, 5% ACN in Milli-Q water; solvent B, va
njection volume, 30 l; flow rate, 0.6 ml/min; sample tray temperature, 8 ◦C; UV ab
rom 0.2 to 0.6 ml/min, thereby decreasing the separation time from
10 min  to 22 min.
The critical method parameters of the RP-UPLC method were
tudied in a screening design of experiments to assess their impact
n the method’s run time and the resolution between the aden-
virus proteins.: The following conditions were evaluated: gradient
tart composition (0–20% solvent B), gradient end composition
45–65% solvent B), gradient run time (17–25 min), TFA concen-
ration (0.04–0.12%), and column temperature (40–70 ◦C). JMP
tatistical software was used to fit a model based on standard least
quares using the main effects of the parameters. The response that
as chosen to study the effect of the tested parameters was the best
esolution between the maximum number of protein peaks with
he shortest run time. From a Pareto-analysis with standardized
arameter estimates it was concluded that the TFA concentra-
ion and the column temperature had the strongest impact on the
esponse. The peaks between approximately 6 and 8 min  (proteins
, VII and VIII) and between 13 and 15 min  (proteins IIIa and IX)
ere most influenced by the column temperature and the TFA con-
entration (Fig. 2A–C and G–J). The best resolution between the
ifferent peaks was obtained at the highest concentration of TFA
0.12%) and a column temperature of 50 ◦C (Fig. 2B). The gradient
tart and end composition and the gradient time were not critical
egarding resolution or elution order, provided the gradient start
omposition was above 10% ACN to assure complete dissociation
f the virus particles and the end composition was above 45% ACN
o allow elution of all adenovirus proteins. Based on this feasibility
xperiment, the gradient start composition was fixed at 20% B and
he end composition at 50% B, with a gradient time of 17 min. These
ettings resulted in the shortest run time with the best resolution
ossible. Initially, solvents A and B were prepared with 0.04–0.12%
FA, however, allowing this range of TFA concentration caused day-
o-day variability (i.e. shifts in retention time), indicating that the
FA concentration is a critical method parameter which needs to
e tightly controlled. Fig. 2A–C shows that TFA has a significant
ffect on the separation even with slight changes from 0.09% to
.12% TFA. The method robustness with respect to this parameter
as examined specifically by design of experiments (see below,
ection 3.1.1). In addition, to increase the reproducibility of the
obile phase composition, the gradient mobile phase preparationlation buffer to a concentration of 2.5 × 1011 vp/ml. Column, Xbridge BEH 300, C4,
 amounts of TFA (see above) in 99% ACN; gradient, 20%–50% solvent B in 17 min.
nce detection at 280 nm.
method was changed as follows: Solvent A was 5% ACN in water,
solvent B was 100% ACN, and solvent C was  1% TFA in 5% ACN. The
UPLC-system was then used to mix  the three solvents to repro-
ducibly obtain constant concentrations of TFA in the mobile phase
throughout the gradient.
3.1.1. Design of experiments – optimization of TFA concentration
and column temperature
The effects of the TFA concentration in the mobile phase and the
column temperature were studied by a 3141 full-factorial design (1
factor at 3 levels and 1 factor at 4 levels) with the aims to reduce
the total run time of the analytical method and to improve the sep-
aration of critical peak pairs: V-VIII(1), VIII(1)-VII, VII-VI(2) (Ad35
only), VI(2)-VI(3) (Ad26 only), II-IX, and IX-IIIa. The selected factors
were: TFA concentration, 0.150, 0.175, or 0.200%; column temper-
ature, 40, 50, 60, or 70 ◦C. The study was  executed by analyzing
both Ad26 and Ad35 samples. The responses that were consid-
ered to evaluate the effects were the retention time of protein II
(used as indicator of the method’s run time) and the separation
of the critical peak pairs (see above). As the protein peak widths
did not significantly change under the tested conditions, the differ-
ences in retention times of the critical peak pairs were used instead
of the resolution as indicator for separation. A protein retention
difference of 0.3 min  or higher corresponded with baseline separa-
tion. The data were processed by JMP  statistical software based on
the factor main effects and interaction effects. For both adenovirus
type 35 (Fig. 3A) and type 26 (Figs. 2E and 3 B) critical peak pairs
were baseline separated in 17 min  using 0.175% TFA and a column
temperature of 50 ◦C. The contour plot in Fig. 4 summarizes the
results of this design of experiments. Peak pairs II-IX and VVIII(1)
were baseline separated at all tested conditions, with a retention
time difference of > 0.6 min  (Fig. 2D–F). For column temperatures
between 40 and 55 ◦C, the separation of peak pair VI(2)VI(3) (Ad26
only) was compromised (resolution 0.8) at a TFA concentration of
0.2% (Fig. 2F), but remained acceptable (baseline resolution) for the
other peak pairs. Column temperatures of 55 ◦C or higher resulted
in insufficient separation for three out of five peak pairs at all TFA
The robustness of the method for small changes in the TFA concen-
tration was  studied by assessing the reproducibility of the retention
times and peak areas. An Ad26 sample was analyzed at four dif-
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Fig. 3. RP-UPLC-UV of A) adenovirus vector type 35 samples and B) adenovirus vector type 26 samples at optimum separation conditions. AI) Adenovirus vector type 35
with  transgene C, AII) Adenovirus vector type 35 with transgene B. BI) Adenovirus vector t
Xbridge  BEH 300, C4, 300 Å, 1.7 m,  2.1 mm x 150 mm.  Solvent A, 5% ACN in Milli-Q water;
TFA  concentration of 0.175%. Injection volume, 30 l; flow rate, 0.6 ml/min; column temp
Fig. 4. Contour plot showing (A) retention time of protein II and (B–E) baseline
separation of critical protein peak pairs as function of the TFA concentration of the
mobile phase and the column temperature as obtained during RP-UPLC of aden-
ovirus type 26. A) dotted line represents a retention time of 13.3 min; green area,
retention time >13.3 min  B–E) peak pairs VI(2)-VI(3) (B), III-II (C), VIII(1)-VII (D), and
IX-IIIa (E); dotted lines represent baseline separation; red area, no baseline separa-
tion; peak pairs II-IX and V-VIII(1) are not depicted as these were baseline separated










t  (For interpretation of the references to colour in this figure legend, the reader is
eferred to the web  version of this article).
erent TFA conditions (with three independent analysis per tested
FA concentration): 0.170, 0.175, 0.180, or 0.185% TFA in the mobile
hase (Fig. 5). The retention times and peak areas for 1.70, 0.180 and
.185% TFA were compared to the retention times and peak areas
or the default conditions (0.175% TFA). The critical peak pairs were
lways baseline separated and the peak areas and retention times
t 1.70, 0.180 and 0.185% TFA did not deviate more than 5% as com-ype 26 with transgene A, BII) Adenovirus vector type 26 with transgene B. Column,
 solvent B, ACN; solvent C, 1% TFA in 5% ACN; gradient, 20%–50% ACN in 17 min with
erature, 50 ◦C; sample tray temperature, 8 ◦C; UV absorbance detection at 280 nm.
pared to the optimal system employing a TFA percentage of 0.175%
in the mobile phase. Based on the results it was concluded that the
method is robust within the concentration range of 0.170 to 0.185%
TFA, provided the mobile phase is prepared as described above in
Section 3.1.
3.2. Protein peak assignment
Peaks were assigned to the respective adenovirus proteins by
separate LC MS  analysis. Due to the presence of TFA in the mobile
phase, it was  not possible to attain accurate mass data form the
intact adenovirus proteins by online coupling to MS.  Therefore,
fractions were collected from the RP-UPLC chromatograms of Ad26
and Ad35, which were digested by trypsin and subsequently ana-
lyzed by RP-HPLC-MSE in order to identify the proteins by peptide
mapping. Peaks observed for both Ad26 and Ad35 (Figs. 3 and 5)
could be assigned to proteins II, III, IIIa, V, VI, VII, VIII, IX, and X.
Multiple fragments from cleavage of proteins VI and VIII were iden-
tified, marked VI(1), VI(2), VI(3) (only in Ad26), VIII(1), and VIII(2)
(only in Ad26). Indeed, maturation of adenovirus into complete,
infectious virus particles involves proteolytic cleavage of capsid
and core proteins by the adenovirus proteinase (AVP), and the
results of peak assignment indicate that the Ad26 sample contains
mature adenovirus particles, The fiber protein (IV) was also iden-
tified and had a retention time of 12.0 min, but the peak height
was very close to the limit of detection of the RP-UPLC-UV method.
The terminal protein could not be identified in the RP-UPLCUV
chromatogram, probably because of its low copy number (n = 2)
in the virus (for comparison: the copy number for protein II is 720).
Proteins 52.55k (1) and (2), assigned in the last two peaks of the
RP-UPLC chromatogram (Fig. 3B), are associated with maturation
of the virus particles and reported only present in immature virus
particles [34,35]. Preliminary data showed that the peak area ratios
of 52.55 K/III, VIII(1)/III and VIII(2)/III are a measure of the relative
concentration of immature adenovirus particles, which is in line
with observations by Takahashi et al. [27] and Vellekamp et al. [28].
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Fig. 5. RP-UPLC-UV of Ad26 sample (three chromatograms overlaid for each %TFA, which 
in  formulation buffer to a concentration of 2.5 × 1011 vp/ml. Other conditions: See Fig. 3.
Table 1
Summary of method repeatability and intermediate precision of the previous
method RP-HPLC [26] and RP-UPLC. The precision is given as overall precision in







Method repeatability (% RSD)
Overall (all proteins, all concentration levels) 6 – 26 1 – 2 1 – 14 0 – 1



























Overall (all proteins, all concentration levels) 8 – 42 1 – 4 1 – 26 0 – 2
Overall, except Protein V 6 – 27 1 – 4 1 – 14 0 – 2
.3. RP-UPLC method validation
The optimized RP-UPLC-UV method is intended for protein pro-
ling of Ad26 and Ad35 vector-based vaccine products. The protein
rofile of the test sample was compared to the profile of a ref-
rence sample based on the relative retention times and relative
eak areas. The first purpose of the comparison was to confirm the
dentity of the adenovirus vector (type 26 or 35) based on match-
ng relative retention times of the detected adenovirus proteins in
he test sample versus the reference (i.e. protein fingerprinting).
he second purpose was to detect potential protein modifications
nd degradation products of the vaccine product, by monitoring
he relative peak areas of all peaks in the chromatogram, including
ny previously unidentified peaks. To validate the method for these
wo purposes, the specificity, precision, accuracy, linearity, and LOQ
ere assessed. The specificity of the method for the adenovirus pro-
eins was demonstrated by MS  during method development (see
aragraph 3.2) and by demonstrating absence of peaks assigned
o the viral proteins in the chromatogram of the formulation buffer
blank). Precision was evaluated as method repeatability and inter-
ediate precision of the relative peak areas and relative retention
imes. The method repeatability of the relative retention times of
ll proteins was between 0.1 and 1% RSD. The method repeatabil-
ty of the relative peak areas was between 1 and 14% RSD, which
as a significant improvement compared to the current RP-HPLC
ethod with a method repeatability of 6–26% RSD (Table 1). The
ntermediate precision of the relative retention times was  0.1–2.0%were 0.170% (A), 0.175% (B), 0.180% (C), or 0.185% (D). The Ad26 sample was diluted
RSD and 1–14% RSD for the relative peak areas (Table 1), which
met  the acceptance criterion for method validation (≤ 20% RSD),
except for the relative peak area for protein V (9–26% RSD), which
was higher than obtained for other proteins and did not meet the
acceptance criterion for method validation. Linearity was demon-
strated for samples diluted with formulation buffer within a range
of 1.0 × 1011 to 2.5 × 1011 vp/ml. The determination coefficients for
the peak areas were between 0.98 and 1.00, based on five concen-
tration levels with three replicates at each level. The accuracy of the
absolute peak areas could not be determined by spiked recovery
due to unavailability of pure adenovirus protein standards. There-
fore, the accuracy was  determined as percentage recovery of the
measured relative peak area against the expected relative peak area
at all concentration levels, based on dilutional linearity of the high-
est concentration level. The recoveries of the relative peak areas
were between 79–108% for all adenovirus proteins. The LOQ of the
method, the lowest concentration level within the linear range with
acceptable precision and accuracy, was 1.0 × 1011 vp/ml. The RP-
UPLC-UV method was  not validated for the quantification of protein
V since the peak area repeatability was  higher than the criterion.
Protein IV, VI(3), VIII(2), 52.55 K (1), 52.55 K (2) could not be quan-
tified because their peak areas were below the limit of detection.
In summary, the method was validated for the quantification of the
relative peak areas of adenovirus proteins II, III, IIIa, VI(1), VI(2), VII,
VIII(1), VIII(2), IX, and X and for the detection of adenovirus pro-
teins IV, V, VI(3), VIII(2), 52.55 K (1), 52.55 K (2) in adenovirus type
26 and type 35 vector-based vaccine products.
3.4. Stability indicating ability of the RP-UPLC-UV method
To assess if the RP-UPLC-UV method can pick up changes in
the protein composition that may  occur during product storage,
Ad26 samples were stressed under different conditions and char-
acterized by several physicochemical and biochemical methods.
The stress conditions comprised oxidation with peroxide or tem-
perature stress at 50 ◦C for 45 and 120 min. The stressed samples
and a non-stressed control sample were analyzed by RP-UPLC-UV
and the chromatograms of the stressed samples were compared to
the control sample based on the relative retention times and rel-
ative peak areas. The same stressed samples were also analyzed
E. van Tricht et al. / J. Chromatogr. 
Fig. 6. Forced degradation of an adenovirus serotype 26 sample as studied by
three analytical methods: CZE, RP-UPLC and a potency assay (infectivity). The bars
show the percentage recovery of the stressed samples in comparison with the























otency assay infectivity recovery and for RP-UPLC total peak area recovery). The
rror bars represent the standard deviations.
y capillary zone electrophoresis [32] and by a potency assay, for
etermination of the concentration of virus particles and the infec-
ivity, respectively. Thermal stress at 50 ◦C for 45 min  resulted in
verall RP-UPLC peak area decreases of approximately 17%. Ther-
al  stress for 120 min  resulted in 56% decrease in overall peak areas
nd, consequently, some proteins were close to the limit of quan-
ification. The relative peak areas of the proteins, however, were
he same in both temperature-stressed samples compared to the
on-stressed sample. The CZE analysis of the temperature-stressed
amples showed a decrease in virus particle concentration of 25%
t 45 min  and 74% at 120 min, which was in line with the peak area
ecrease of the RP-UPLC chromatograms (Fig. 6). This suggests that
emperature stress resulted in loss of virus particles rather than
pecific degradation of adenovirus proteins. For the same samples,
he infectivity decreased by 22% and 91% for stress times of 45 and
20 min, respectively. Oxidative stress resulted in the loss of almost
ig. 7. RP-UPLC-UV chromatograms of process intermediate samples A) Adenovirus type 
ntermediate sample with unknown peaks detected at 2 and 9 min. C) adenovirus type 26 p
)  Adenovirus type 26 reference sample. Conditions: See Fig. 3.A 1581–1582 (2018) 25–32 31
all adenovirus proteins (approx. 91% overall chromatogram peak
area decrease) and a number of new peaks were observed in the
chromatogram, which were tentatively assigned to oxidized aden-
ovirus proteins. The relative peak areas did change after oxidation
stress due to the new peaks. The virus particle concentration mea-
sured by CZE decreased by 88% and the infectivity decreased by
99%, which indicated that almost all the adenovirus particles were
degraded in the oxidized sample. The RP-UPLC method is sensitive
for temperature stress and oxidative stress.
3.5. Application of RP-UPLC method to adenovirus process
samples
The validated method was  implemented for the analysis of
adenovirus-based products. Some examples are provided in Fig. 7
and further described below.
Fig. 7A shows the chromatogram of an Ad26 process intermedi-
ate sample which was  stored for 9 months at 5 ◦C (normal storage
condition of final product is −80 ◦C). All peak areas decreased by a
factor of 3 compared to the reference sample (Fig. 7d). Moreover, a
degradation product was  observed as shoulder of the peak of pro-
tein II at 12.9 min. This peak was identified by MS  as intact protein
II with oxidation and deamidation modifications.
Fig. 7B shows a partially purified sample from downstream
processing. Additional peaks were detected in the RP-UPLC chro-
matogram at 2 and 9 min. The DAD spectra of these peaks did
not show the typical protein spectrum characteristics. Fractions
containing these peaks were collected and analyzed by GC–MS
and LC–MS. The peaks at 2 min  and 9 min  were assigned to 2,4-
dimethylbenzaldehyde and 2,4 di tert-butylphenol, respectively.
These could be leachables from the disposable container bags used
in the process. Trace C in Fig. 7 is from another partially puri-
fied process intermediate sample with high concentrations of host
cell protein impurities. The DAD spectra of the additional peaks
showed typical protein-spectra, however the relative peak areas
of the adenovirus proteins were unchanged compared to the ref-
erence sample. In this case, fractions of the additional peaks were11 and 13 min  were assigned to host cell proteins, which were
present at high concentrations and could therefore be detected by
the RP-UPLC method.
26 process intermediate stored at 5 ◦C for 9 months. B) Adenovirus type 26 process













































2 E. van Tricht et al. / J. Chrom
. Conclusions
An RP-UPLC method was developed and validated for protein
rofiling of adenovirus type 26 and type 35 proteins. Compared
ith a currently used RP-HPLC method, the method’s run time was
ecreased from 130 min  to 17 min, allowing for the analysis of up
o 50 samples per day instead of 10. Protein profile changes were
bserved upon oxidative stress of adenovirus samples, indicating
hat the method can be used to monitor stability of adenovirus
ector-based vaccines. Analysis of process intermediate samples
howed the ability of the RP-UPLC method to detect and possi-
ly quantify protein degradants, leachables, and host cell protein
mpurities. Future method development will be directed towards
nhancing the sensitivity of the RP-UPLC method to be able to
ccurately quantify protein IV (the fiber protein). For example,
lternative detection modes such as fluorescence will be explored.
he new RP-UPLC method is a useful addition to the analytical
oolbox for the analysis of adenovirus-based products, as it allows
or the rapid and accurate quantification of the adenovirus protein
rofile and any protein degradation products.
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